Imiquimod 5% cream in the treatment of human papillomavirus-16-positive erythroplasia of Queyrat.
Erythroplasia of Queyrat is a human-papillomavirus-associated carcinoma in situ of the penis. Imiquimod, a new topically applied immunomodulatory agent, has been successfully used in the treatment of anogenital warts. We report the complete clearance of HPV-16-positive erythroplasia of Queyrat with 5% imiquimod cream.
Kaspari
Markus
M
Department of Dermatology and Allergology, Hannover Medical University, Germany. tahama@t-online.de
Gutzmer
Ralf
R
Kiehl
Peter
P
Dumke
Pia
P
Kapp
Alexander
A
Brodersen
Jens P
JP
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000287:Administration, Topical; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D004919:Erythroplasia / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D000077271:Imiquimod; D008297:Male; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D010412:Penile Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D010413:Penis / Q000473:pathology; D014412:Tumor Virus Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod